Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals (KERX) to Buy
Tweet Send to a FriendGet Alerts KERX Hot Sheet
Price: $7.88 -2.11%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade KERX Now!
Ladenburg Thalmann upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Buy, new price target of $3.00.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $1.45 yesterday, with a 52 week range of $1.28-$5.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $1.45 yesterday, with a 52 week range of $1.28-$5.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
- Sterne Agee Upgrades Cree (CREE) to Buy
- NetApp (NTAP) Post Solid Q4, Numbers Bumped - Needham & Company
Create E-mail Alert Related Categories
UpgradesRelated Entities
Ladenburg Thalmann Financial Services
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
